Project Grant R01HL169611
Award Date
7/15/24
Completion Date
6/30/29
Dollars Obligated
$595K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
This $5,715,866 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of pulmonary fibrosis (PF). The 5-year program will focus on investigating the early, pre-symptomatic progression of familial pulmonary fibrosis (FPF) to identify critical mechanisms driving disease initiation and progression. Key activities include: Analyzing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,546,880.00 to the University of Pittsburgh to conduct research on the regulation of myofibroblasts in idiopathic pulmonary fibrosis (IPF). The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, evaluate how expression of E-box transcription factors regulates myofibroblast...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $2,323,927 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The grant will fund research to investigate the emergence, fate, and functional role of inflammatory fibroblasts in the development of pulmonary fibrosis. Key objectives include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $542,402 in funding to support research conducted by the collaborative partnership between Henry Ford Health and Michigan State University Health Sciences. The goal of the project is to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a devastating lung disease...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...
This $313,632 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a 5-year research project led by Dr. Joseph Cooley at National Jewish Health in Denver, Colorado. The project aims to investigate how the signaling molecule interleukin-6 (IL-6) promotes resistance to cell death (apoptosis) in lung fibroblasts, which is a key mechanism driving progressive pulmonary fibrosis. Specifically, the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research to understand the role of alveolar epithelial cell stress signaling in the pathogenesis of pulmonary fibrosis. The award, made under the Cardiovascular Diseases Research Program (CFDA 93.837), totals $683,564 and is effective from July 1, 2025 through March 31, 2030. The research aims to elucidate how aberrant transitional alveolar type 2...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...